Under this programme, employees can work on innovative ideas, for which the firm will provide funding and help in setting up a team. The programme is part of the company's initiative to allocate 10 per cent of their cash reserve to initiatives that are technology-led.
In a twist to the tale of drug patent infringement cases in the United States, Indian drug company Lupin has sued Ranbaxy Laboratories, which is now controlled by Japanese drug major Daiichi Sankyo, in an American court.
Capgemini, which reported revenue of 8.4 billion in 2009, is perhaps the only European IT services firm to have successfully used its India centre as an innovation hub, as a large offshoring centre and tap the domestic market for growth.
India Inc's bear hug with Russian consumers is getting warmer. From selling marquee cars to liquor, the relationship is heading into the next league -- joint ventures in diverse areas such as petrochemicals, telecom, pharmaceuticals and nanotechnology.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
Firstsource raised $275 million (around Rs 1,265 crore) through foreign currency convertible bonds in 2007 to fund the acquisition of MedAssist.
Lavasa, Wipro, Cisco combine to launch something new in urban living.
The US celebrates its independence day on July 4. But since it was Sunday, the American government had declared Monday as a holiday.
Shares of Indian software majors have plunged into red on news that BP would cut its spend on information technology.
Research firm Gartner today reported that worldwide IT spending will touch $3.350 trillion--an increase of 3.9 per cent from 2009. However, it simultaneously lowered its outlook for the IT industry from the first quarter of this calendar year, when it had forecast worldwide IT spending to grow 5.3 per cent. This is primarily due to the devaluation of the euro versus US dollar since the beginning of the year.
Whitehurst talks about India expansion plans, its latest offering in cloud computing and India's most ambitious project Aadhaar.
L&T plans to transfer the equity of L&T in their joint ventures with Mitsubishi Heavy Industries into L&T Power through a book transfer, if clauses for the re-tender remain the same, company executives told Business Standard.
With the economy giving positive signals, hiring is back. However, so is attrition, with disgruntled employees demanding more or moving to greener pastures to make up for lost time and money.
Plans to set up an integrated pharma firm in a phased manner.
Mukesh Ambani's Reliance Industries Ltd may be one of the biggest producers of natural gas in the country, but its power foray is likely to be coal or renewable energy based. The company is planning to not only bid for ultra mega power projects but also go in for acquisition of the power plants, said industry sources.
Low delinquency rates, huge demand attract investors to the unique gold financing sector.
US-based Abbott Laboratories has sued Sun Pharmaceutical Industries and Ranbaxy Laboratories in courts there for challenging the patents of its cholesterol-lowering drugs, Niaspan and TriCor, respectively, in separate infringement suits.
Domestic information technology services majors Tata Consultancy Services, Wipro Technologies and Tech Mahindra and global players like IBM and Japan-based NEC are among the 10 shortlisted companies for the Nandan Nilekani-headed Unique Identification Authority of India biometrics job.
Sites like Facebook and Orkut may be great for connecting with others, but they also provide a sure-fire way for broadcasting intimate details about you.
The Aditya Birla Group has received in-principle approval from the Kerala government to set up a Rs 4,000-crore (Rs 40 billion) IT and Biotech Knowledge Park and a branch of Birla Institute of Technology and Sciences (BITS) at Kozhikode.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances